Fig 1.
Simplified Markov model of empirical chemotherapy, EGFR mutation-guided afatinib, erlotinib, and gefitinib for treatment of advanced NSCLC.
EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer.
Table 1.
Model inputs.
Table 2.
Expected direct medical cost, progression-free survival (PFS) months, overall-survival (OS) months, and quality-adjusted life-years (QALYs) in base-case analysis.
Table 3.
Base-case analysis of increment cost, incremental QALYs and incremental cost per QALY gained (ICER).
Fig 2.
Scatter plot of incremental cost against QALY gained by EGFR mutation-guided afatinib versus empirical chemotherapy.
QALY: quality-adjusted life-year; WTP: willingness-to-pay.
Fig 3.
Scatter plot of incremental cost against QALY gained by EGFR mutation-guided erlotinib versus empirical chemotherapy.
QALY: quality-adjusted life-year; WTP: willingness-to-pay.
Fig 4.
Scatter plot of incremental cost against QALY gained by EGFR mutation-guided gefitinib versus empirical chemotherapy.
QALY: quality-adjusted life-year; WTP: willingness-to-pay.
Fig 5.
Scatter plot of incremental cost against QALY gained EGFR mutation-guided afatinib versus EGFR mutation-guided erlotinib.
QALY: quality-adjusted life-year; WTP: willingness-to-pay.
Fig 6.
Acceptability curves of empirical chemotherapy, EGFR mutation-guided afatinib, erlotinib, and gefitinib for treatment of advanced NSCLC to be cost-effective against willingness-to-pay.
EGFR: epidermal growth factor receptor; NSCLC: non-small-cell lung cancer.